Neurovascular unit uncoupling in diabetic retinopathy: molecular mechanisms and stage-adapted therapeutic strategies - Report - MDSpire

Neurovascular unit uncoupling in diabetic retinopathy: molecular mechanisms and stage-adapted therapeutic strategies

  • By

  • Jing Chen

  • Ling Zhang

  • July 1, 2026

  • 0 min

Share

Clinical Report: Disruption of the Neurovascular Unit in Diabetic Retinopathy

Overview

Diabetic retinopathy (DR) is increasingly recognized as a neurovascular degenerative disorder, with early neuronal dysfunction preceding visible vascular lesions. This review discusses the molecular pathways involved in DR.

Background

Diabetic retinopathy is a significant cause of vision loss among adults, affecting over 100 million individuals globally. Traditionally viewed as a microvascular complication, recent insights reveal that DR involves interactions among neuronal, glial, and vascular components of the retinal neurovascular unit.

Data Highlights

No numerical data provided in the article.

Key Findings

  • Diabetic retinopathy is a neurovascular degenerative disorder, not solely a microvascular complication.
  • Chronic hyperglycemia and oxidative stress disrupt the retinal neurovascular unit, leading to neurovascular uncoupling.
  • Functional abnormalities in DR can occur before visible vascular lesions are detected.
  • Current therapies primarily target advanced disease.

Clinical Implications

Recognizing diabetic retinopathy as a disorder of the neurovascular unit may facilitate earlier diagnosis.

Conclusion

Reframing diabetic retinopathy as a neurovascular disorder emphasizes the importance of early detection.

Related Resources & Content

  1. Retinal Physician, New Strategies for Managing Diabetic Retinopathy, 2026
  2. The Ophthalmologist, Resveratrol and Diabetic Retinopathy, 2026
  3. Optometric Management, Staging and Practical Management of Diabetic Retinopathy, 2026
  4. Diabetes Care, 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026
  5. Retinal Physician — New Pathways for Diabetic Macular Edema Therapy
  6. Diabetic Retinopathy Preferred Practice Pattern® - Ophthalmology
  7. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026 - PMC
  8. Diabetic Retinopathy Preferred Practice Pattern® - Ophthalmology
  9. EVIDENCE-BASED CLINICAL PRACTICE GUIDELINE
  10. Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy - PMC
  11. Effect of Aflibercept, Laser Photocoagulation, or Observation on Vision Loss in Diabetic Macular Edema
  12. IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS - PubMed
  13. Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials - PMC
  14. Diabetic retinopathy: management and monitoring - NCBI Bookshelf
  15. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2026 | Diabetes Care | American Diabetes Association

Original Source(s)

Related Content